TaiRx, Inc.
TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various … Read more
TaiRx, Inc. - Asset Resilience Ratio
TaiRx, Inc. (6580) has an Asset Resilience Ratio of 49.25% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how TaiRx, Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down TaiRx, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$300.00 Million | 49.25% |
| Total Liquid Assets | NT$300.00 Million | 49.25% |
Asset Resilience Insights
- Very High Liquidity: TaiRx, Inc. maintains exceptional liquid asset reserves at 49.25% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
TaiRx, Inc. Industry Peers by Asset Resilience Ratio
Compare TaiRx, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for TaiRx, Inc. (2019–2024)
The table below shows the annual Asset Resilience Ratio data for TaiRx, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 58.41% | NT$400.00 Million | NT$684.78 Million | -1.56pp |
| 2023-12-31 | 59.97% | NT$500.00 Million | NT$833.75 Million | -0.58pp |
| 2022-12-31 | 60.55% | NT$323.38 Million | NT$534.04 Million | -11.72pp |
| 2021-12-31 | 72.27% | NT$510.68 Million | NT$706.62 Million | +2.68pp |
| 2020-12-31 | 69.59% | NT$582.68 Million | NT$837.30 Million | +13.47pp |
| 2019-12-31 | 56.12% | NT$274.62 Million | NT$489.34 Million | -- |